Full-Time

Lead Engineer

Evidence Management

Updated on 9/12/2026

Deadline 9/18/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$102k - $175.9k/yr

Raritan, NJ, USA + 1 more

More locations: Limerick, Ireland

Hybrid

Primarily hybrid; candidates should be within commuting distance of a Johnson & Johnson office. Limited remote consideration may be available for strong credentials.

Bachelor's

Category
Software Engineering
Required Skills
LLM
Agile
Machine Learning
RAG
Cybersecurity
Role-based Access Control
REST APIs

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • A bachelor's degree in Computer Science, Engineering, Information Systems, Data Science, AI/ML, or a related field.
  • At least 10 years of progressive experience in software engineering, application architecture, solution architecture, platform architecture, low-code platform architecture, data architecture, or enterprise technology delivery.
  • Hands-on experience engineering, architecting, and delivering solutions on the Appian platform.
  • Expertise in Appian solution design, including process modeling, interfaces, records, integrations, data models, rules, reports, role-based security, application lifecycle governance, and environment management.
  • Experience leading application engineering delivery in Agile or Scaled Agile Framework environments, including backlog shaping, technical design, code quality, release readiness, dependency management, and production support considerations.
  • Experience architecting or engineering artificial-intelligence-enabled enterprise solutions, including Generative AI and/or Machine Learning use cases.
  • Hands-on knowledge of Large Language Models, prompt engineering, semantic search, vector databases, Retrieval-Augmented Generation, model orchestration, AI observability, and responsible AI controls.
  • Experience designing secure, cloud-native, API-enabled, workflow-enabled, and data-centric platforms in complex enterprise environments.
  • Experience supporting regulated business functions such as Regulatory Affairs, Scientific Affairs, Quality, Clinical, Safety, Research and Development, or Life Sciences technology.
  • Working knowledge of GxP, SOX, privacy, cybersecurity, data integrity, regulated software development life cycle, validation, qualification, or computerized system assurance practices.
  • Ability to translate business operating models, regulatory processes, and evidence management needs into scalable technical architectures and delivery-ready engineering designs.
Responsibilities
  • Serve as the Lead Engineer for evidence management capabilities covering regulatory and scientific workflow, case management, process automation, content and data flows, integrations, and user experience.
  • Define and guide application architecture for platforms supporting regulatory planning, submissions, evidence intake, evidence assessment, regulatory intelligence, workflow automation, post-approval activities, scientific evidence collaboration, and analytics.
  • Maintain primary focus on Regulatory Affairs delivery priorities while designing solutions that support Scientific Affairs processes, evidence workflows, and cross-functional collaboration.
  • Lead AI-enabled modernization by identifying high-value evidence management use cases, designing scalable implementation patterns, and ensuring responsible adoption in regulated environments.
  • Partner with Regulatory Affairs, Scientific Affairs, Quality, Research and Development, Supply Chain, Cybersecurity, Privacy, Data Governance, and Information Technology delivery teams to translate complex business needs into compliant, maintainable technology solutions.
  • Act as the lead technical advisor for Appian application decisions, integrations, data products, engineering practices, and AI-enabled capabilities across the evidence management ecosystem.
  • Own and maintain the application architecture strategy and engineering roadmap for evidence management capabilities across Regulatory Affairs and Scientific Affairs.
  • Design scalable, interoperable, and compliant solutions across regulatory platforms, Appian applications, data flows, workflows, integrations, content repositories, and analytics capabilities.
  • Translate complex regulatory and scientific evidence processes into practical application designs, engineering patterns, data models, and delivery backlogs.
  • Drive design governance for new capabilities, major enhancements, technical debt remediation, platform modernization, and cross-system interoperability.
  • Ensure solution designs align with enterprise standards for cloud, cybersecurity, privacy, lifecycle management, supportability, and technical sustainability.
  • Lead engineering and application architecture for Appian-based regulatory workflow, evidence case management, process automation, integration, records, reporting, and user experience capabilities, and define Appian design standards.
  • Maintain understanding of Regulatory Affairs operating processes and technology needs across planning, submissions, regulatory intelligence, workflow orchestration, post-approval activities, content management, compliance, and analytics.
  • Ensure evidence management capabilities support traceability, auditability, role-based access, status visibility, decision history, and inspection-ready records where required.
  • Extend evidence management architecture and engineering patterns to support Scientific Affairs use cases such as evidence intake, evidence evaluation, collaboration workflows, knowledge search, scientific content traceability, and analytics.
  • Identify common process, data, content, workflow, and integration patterns that can be reused across Scientific Affairs and Regulatory Affairs while respecting domain-specific controls.
  • Define the AI-enabled engineering roadmap for evidence management, including Generative AI, Machine Learning, Natural Language Processing, semantic search, knowledge graphs, agentic workflows, and intelligent automation where appropriate.
  • Guide proof-of-concepts, pilots, and scaled implementations for AI capabilities with business value, security, usability, and compliance controls.
  • Establish patterns for monitoring, hallucination risk mitigation, source traceability, human-in-the-loop review, prompt and version governance, and model performance evaluation.
  • Define data architecture principles for evidence metadata, Appian data models, regulatory master data, scientific evidence content, operational data, unstructured content, and analytics-ready data products.
  • Establish engineering standards for application programming interfaces, event-driven integration, workflow orchestration, data lineage, data quality, access control, and platform interoperability.
  • Ensure engineering and architecture decisions support GxP, SOX, privacy, cybersecurity, auditability, data integrity, validation or qualification expectations, and regulated software development life cycle or computerized system assurance practices.
  • Partner with Quality, Security, Privacy, Regulatory Affairs, Scientific Affairs, and Data Governance stakeholders to assess technology, Appian-specific, evidence-management-specific, and AI-specific risks.
Desired Qualifications
  • Appian certification or equivalent demonstrated enterprise Appian engineering and architecture experience.
  • Experience with Regulatory Affairs platforms, regulatory information management solutions, submission management, regulatory intelligence, regulatory analytics, content management, knowledge management systems, or evidence management platforms.
  • Experience supporting Scientific Affairs, Medical Affairs, evidence generation, scientific content workflows, or knowledge search capabilities.
  • Experience with Microsoft Azure AI services, Azure OpenAI, Copilot extensibility, AI Foundry, agent frameworks, or equivalent enterprise AI platforms.
  • Experience applying AI in regulated environments, including human-in-the-loop workflows, validation strategy, model monitoring, data governance, and risk-based controls.
  • Architecture, engineering, or Agile certifications such as TOGAF, Azure Solutions Architect, Appian certification, SAFe Architect, SAFe Agilist, or equivalent.
  • Experience leading vendor technology assessments, Appian solution reviews, AI platform evaluations, proof-of-concepts, and enterprise-scale implementation planning.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Carvykti topped $1 billion annual sales in January 2026, strengthening oncology.
  • IMAAVY won FDA approval on August 24, 2026, expanding a second launch.
  • Q2 2026 sales rose 6.6% to $25.31 billion, and guidance increased.

What critics are saying

  • The July 2026 talc settlement covers only existing claims, leaving future lawsuits open.
  • CVS dropped Stelara from main formularies in May 2026, accelerating biosimilar pressure.
  • Carvykti’s FDA boxed warning and Legend partnership constrain multiple myeloma expansion.

What makes Johnson & Johnson unique

  • J&J spans Innovative Medicine and MedTech, reducing dependence on any single franchise.
  • Carvykti and IMAAVY show J&J still converts R&D into first-in-class approvals.
  • Its oncology and immunology franchises offset Stelara’s erosion.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.

Yahoo Finance
Aug 29th, 2026
AbbVie vs. Johnson & Johnson: Which healthcare stock offers better value in 2026?

AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.

Yahoo Finance
Aug 28th, 2026
JNJ stock surges 54% as TREMFYA's $2B quarter offsets STELARA's biosimilar decline

Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.